Get access

Emerging molecular networks in Burkitt's lymphoma

Authors

  • Davide Mangani,

    1. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA
    2. Human Health Foundation, Terni and Spoleto (PG), Italy
    Search for more papers by this author
  • Annalisa Roberti,

    1. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA
    Search for more papers by this author
  • Flavio Rizzolio,

    1. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA
    2. Experimental and Clinical Pharmacology - National Cancer Institute IRCCS Aviano, Italy
    Search for more papers by this author
  • Antonio Giordano

    Corresponding author
    1. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA
    2. Department of Human Pathology and Oncology, University of Siena, Siena, Italy
    • Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, 1900N. 12th Street, Bio Life Sciences Building Suite 431, Philadelphia, PA 19122.
    Search for more papers by this author

  • The authors declare no conflict of interest.

Abstract

Burkitt's lymphoma (BL), one of the most aggressive tumors affecting humans, characterized by the constitutive activation of the Myc oncogene together with the alteration of many other genetic and epigenetic factors. Among them, the INK4a/ARF locus has been well documented to play a central role in BL. Recently, we have discovered that simultaneous deregulation of both DNA methylation patterns and the ubiquitin-dependent proteolysis system is required to completely inactive the INK4/ARF locus, opening new possibilities for treating Burkitt's lymphoma. In this review, we integrate our discovery with the general view of BL and propose a new comprehensive approach to analyze and manage this aggressive disease. J. Cell. Biochem. 114: 35–38, 2012. © 2012 Wiley Periodicals, Inc.

Get access to the full text of this article

Ancillary